Akebia Therapeutics, Inc. (NASDAQ:AKBA) is set to announce third quarter earning results on Thursday 5th November 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, AKBA to report 3Q20 loss of $ 0.17 per share.
For the full year, analysts anticipate top line of $ 324.22 million, while looking forward to loss of $ 2.33 per share bottom line.
Previous Quarter Performance
Akebia Therapeutics, Inc. posted loss for the second quarter of $ 0.44 per share, from the revenue of $ 90.14 million. The quarterly revenues contracted 1.09 percent compared with the same quarter last year. Street analysts expected Akebia Therapeutics, Inc. to report loss of $ 0.50 per share on revenue of $ 74.18 million for the second quarter. The bottom line results beat street analysts by $ 0.06 or 12.00 percent, at the same time, top line results outshined analysts by $ 15.96 million or 21.52 percent.
Stock Performance
Shares of Akebia Therapeutics, Inc. traded up $ 0.15 or 6.20 percent on Wednesday, reaching $ 2.57 with volume of 7.93 million shares. Akebia Therapeutics, Inc. has traded high as $ 2.60 and has cracked $ 2.43 on the downward trend
The closing price of $ 2.57, representing a 15.79 % increase from the 52 week low of $ 2.09 and a 82.35 % decrease over the 52 week high of $ 13.71.
The company has a market capital of $ 368.32 million and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 26th October 2020, maintained by HC Wainwright at Buy rating, with $ 9.00 target price.
Conference Call
Akebia Therapeutics, Inc. will be hosting a conference call at 9:00 AM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.akebia.com
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its lead product candidate includes Auryxia, a ferric citrate to control the serum phosphorus levels in adult patients with chronic kidney disease (CKD), on dialysis (DD)-CKD, or the hyperphosphatemia indication (HIF); and vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to CKD in DD and non-dialysis patients. It has collaboration agreements with Otsuka Pharmaceutical Co.
